Vandetanib Available for Advanced Medullary Thyroid Cancer - ONA
Links shared publicly online about this topic.
- 339total visits
Vandetanib Available for Advanced Medullary Thyroid Cancer - ONA
View full resource at oncologynurseadvisor.com
Tags: Cancer, Thyroid Cancer, Medullary Thyroid Cancer, Disease and Condition, AstraZeneca, disease
Most Recently Shared on April 25, 2011 at 7:05 pm By:
Vandetanib Available for Advanced Medullary Thyroid Cancer http://goo.gl/fb/Z5ApL
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial - OncologySTAT
oncologystat.com — “2011 Oct 24;[Epub Ahead of Print] - SA Wells Jr, BG Robinson, RF Gagel, H Dralle, JA Fagin, M Santoro, E Baudin, R Elisei, B Jarzab, JR Vasselli, J Read, P Langmuir, AJ Ryan, MJ Schlumberger” View full resource at oncologystat.com
Most Recently Shared on November 3, 2011 at 5:24 pm By:
OncologySTAT Oncology and Health Site
Story of the Week: Vandetanib Effective in Advanced Medullary Thyroid Cancer http://t.co/CA1KGTDj
CAPRELSA - New Product Releases - MPR
empr.com — “Symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.” View full resource at empr.com
Most Recently Shared on August 5, 2011 at 3:04 pm By:
MPR News: CAPRELSA: Vandetanib 100mg, 300mg, tabs. http://bit.ly/qM5dba
AstraZeneca announces U.S. availability of vandetanib for rare medullary thyroid cancer
news-medical.net — “AstraZeneca today announced that the orphan drug vandetanib is now available to U.S. patients for the treatment of medullary thyroid cancer that cannot be removed by surgery or that has spread to other parts of the body.” View full resource at news-medical.net
Most Recently Shared on April 25, 2011 at 6:12 pm By:
News-Medical.Net Oncology and Health News
Oncology News: AstraZeneca announces U.S. availability of vandetanib for rare medullary thyroid cancer: AstraZen... http://bit.ly/fDCzBW
Vandetanib Available for Advanced Medullary Thyroid Cancer - MPR
empr.com — “AstraZeneca has made available vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.” View full resource at empr.com
Most Recently Shared on April 25, 2011 at 2:19 pm By:
MPR News: Vandetanib Available for Advanced Medullary Thyroid Cancer: AstraZeneca has made available vandetanib ... http://bit.ly/hxrm59
FDA Approves Orphan Drug Vandetanib for Advanced Medullary Thyroid Cancer
drugs.com — “Vandetanib is used to treat advanced medullary thyroid cancer. Includes vandetanib side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on April 11, 2011 at 12:50 am By:
FDA Approves Orphan Drug Vandetanib for Advanced Medullary Thyroid Cancer - http://bit.ly/hiHKy2
FDA Approves Orphan Drug Vandetanib For Advanced Medullary Thyroid Cancer
medicalnewstoday.com — “AstraZeneca (NYSE: AZN) has announced that the U.S. Food and Drug Administration (FDA) approved the orphan drug vandetanib for the treatment of medullary thyroid cancer that cannot be removed by s” View full resource at medicalnewstoday.com
Most Recently Shared on April 8, 2011 at 9:05 am By:
NatureRevEndocrinol Endocrinology and Medical Journal
RT @mnt_endocrine: FDA Approves Orphan Drug Vandetanib For Advanced Medullary Thyroid Cancer http://mnt.to/3Tpj #endocrinology
Vandetanib Approved for Metastatic Medullary Thyroid Cancer - MPR
empr.com — “The FDA has approved the orphan drug vandetanib (AstraZeneca), a kinase inhibitor, for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.” View full resource at empr.com
Most Recently Shared on April 7, 2011 at 2:19 pm By:
MPR News: Vandetanib Approved for Metastatic Medullary Thyroid Cancer: The FDA has approved the orphan drug vand... http://bit.ly/eF20pY
US FDA Advisory Committee Makes Recommendation on New Drug Application for Vandetanib in Advanced Medullary Thyroid Cancer
drugs.com — “Zactima (vandetanib) is a new drug in development for the treatment of advanced non-small cell lung cancer and advanced medullary thyroid cancer. Zactima information includes news, clinical trial results and side effects.” View full resource at drugs.com
Most Recently Shared on December 8, 2010 at 12:11 am By:
Drugs and Devices OW OW Health
US FDA Advisory Committee Makes Recommendation on New Drug Application for Vandetanib in Advanced Medullar... http://bit.ly/hJm7oO #drug
US FDA Advisory Committee Makes Recommendation On New Drug Application For Vandetanib In Advanced Medullary Thyroid Cancer
medicalnewstoday.com — “AstraZeneca (NYSE: AZN) announced the outcome of the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee meeting to discuss the New Drug Application (NDA) for AstraZeneca's in” View full resource at medicalnewstoday.com
Most Recently Shared on December 3, 2010 at 7:05 pm By:
MNT Ear, Nose Throat Health News
US FDA Advisory Committee Makes Recommendation On New Drug Application For Vandetanib In Advanced Medullary Thyroid Ca... http://mnt.to/3Nxg
US And EU Regulatory Submissions For Vandetanib In Advanced Medullary Thyroid Cancer Accepted For Review
medicalnewstoday.com — “AstraZeneca today announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted regulatory submissions for review of the investigational drug vande” View full resource at medicalnewstoday.com
Most Recently Shared on September 24, 2010 at 5:05 pm By:
US And EU Regulatory Submissions For Vandetanib In Advanced Medullary Thyroid Cancer Accepted For Review http://mnt.to/3Khs #endocrinology
US and EU regulatory submissions for VANDETANIB in advanced medullary thyroid cancer accepted for review
astrazeneca.com — “AstraZeneca Press Release” View full resource at astrazeneca.com
Most Recently Shared on September 23, 2010 at 12:58 pm By:
Lisa Jarvis Science Enthusiast
AstraZeneca's thyroid cancer drug vandetanib gets fast track status, PDUFA data Jan 7: http://bit.ly/bsejLa
FDA and EMA accept regulatory submissions of vandetanib for advanced medullary thyroid cancer
news-medical.net — “AstraZeneca today announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted regulatory submissions for review of the investigational drug vandetanib in the treatment of patients with advanced medullary thyroid cancer (MTC). The FDA also granted priority review status for the new drug application and set a Prescription Drug User Fee Act (PDUFA) action date of 7 January 2011.” View full resource at news-medical.net
Most Recently Shared on September 23, 2010 at 9:20 am By:
FDA and EMA accept regulatory submissions of vandetanib for advanced medullary thyroid cancer: AstraZeneca today a... http://bit.ly/9QqF9U
Vandetanib may be effective option for treatment of advanced hereditary medullary thyroid cancer | HemOncToday
hemonctoday.com — “Vandetanib, a selective inhibitor of <I” View full resource at hemonctoday.com
Most Recently Shared on January 22, 2010 at 1:30 pm By:
HemOnc Today Health News and Oncology
#JCO Vandetanib may be effective option for treatment of advanced hereditary medullary thyroid cancer http://ow.ly/Zk6p
Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
jco.ascopubs.org — “Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer” View full resource at jco.ascopubs.org
Most Recently Shared on January 13, 2010 at 2:02 am By:
Mark Robson Oncologist, Hematologist, Physician, Doctor, and Internist
Vandetanib for the Treatment of Patients With Hereditary Medullary Thyroid Cancer http://bit.ly/6yvIAr
Advertisement
